FDA Draft Guidance on the Naming of Biosimilars.
Sara
S
Fernandez-Lopez
D016907:Adverse Drug Reaction Reporting Systems; D059451:Biosimilar Pharmaceuticals; D017408:Guidelines as Topic; D060735:Pharmacovigilance; D009626:Terminology as Topic; D014481:United States; D014486:United States Food and Drug Administration
D059451:Biosimilar Pharmaceuticals